Phenoxybenzamine is neuroprotective in a rat model of severe traumatic brain injury

International Journal of Molecular Sciences

Volumn 15, Issue 1, 2014, Pages 1402-1417

  Rau, Thomas F ^a   Kothiwal, Aakriti ^a   Rova, Annela ^a   Rhoderick, Joseph F ^a   Poulsen, David J ^a  

^a UNIVERSITY OF MONTANA   (United States)

Author keywords

Morris water maze; Neuroprotection; Phenoxybenzamine; Traumatic brain injury

Indexed keywords

INTERLEUKIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOID DIFFERENTIATION FACTOR 88; PHENOXYBENZAMINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; INJURY SCALE; INJURY SEVERITY; LEARNING; MALE; MEMORY; MORRIS WATER MAZE TEST; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; POLYMERASE CHAIN REACTION; RAT; RNA ISOLATION; TRAUMATIC BRAIN INJURY;

ANIMALS; BRAIN; BRAIN INJURIES; CELL DEATH; CELL SURVIVAL; CELLS, CULTURED; CHEMOKINE CCL2; DRUG EVALUATION, PRECLINICAL; INTERLEUKIN-1BETA; MAZE LEARNING; MEMORY; MYELOID DIFFERENTIATION FACTOR 88; NEURONS; NEUROPROTECTIVE AGENTS; PHENOXYBENZAMINE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84892705852     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms15011402     Document Type: Article

References (52)

1. Faul, M.; Xu, L.; Wald, M.; Coronado, V. Traumatic Brain Injury in the United States: Emergency Department Visits, Hospitalizations and Deaths 2002-2006; CDC: Atlanta, GA, USA, 2006.
2. Dempsey, K.E.; Dorlac, W.C.; Martin, K.; Fang, R.; Fox, C.; Bennett, B.; Williams, K.; Flaherty, S. Landstuhl Regional Medical Center: Traumatic brain injury screening program. J. Trauma Nurs. 2009, 16, 6-7.
3. Dean, P.J.; O'Neill, D.; Sterr, A. Post-concussion syndrome: Prevalence after mild traumatic brain injury in comparison with a sample without head injury. Brain Inj. 2011, 26, 14-26.
4. Barth, J.T.; Diamond, R.; Errico, A. Mild head injury and post concussion syndrome: Does anyone really suffer? Clin. Electroencephalogr. 1996, 27, 183-186.
5. Beauchamp, K.; Mutlak, H.; Smith, W.R.; Shohami, E.; Stahel, P.F. Pharmacology of traumatic brain injury: Where is the "golden bullet"? Mol. Med. 2008, 14, 731-740.
6. Blaylock, R.L.; Maroon, J. Immunoexcitotoxicity as a central mechanism in chronic traumatic encephalopathy-A unifying hypothesis. Surg. Neurol. Int. 2011, 2, 107.
7. Roozenbeek, B.; Maas, A.I.; Menon, D.K. Changing patterns in the epidemiology of traumatic brain injury. Nat. Rev. Neurol. 2013, 9, 231-236.
8. Arand, M.; Melzner, H.; Kinzl, L.; Bruckner, U.B.; Gebhard, F. Early inflammatory mediator response following isolated traumatic brain injury and other major trauma in humans. Langenbecks Arch. Surg. 2001, 386, 241-248.
9. Baugh, C.M.; Stamm, J.M.; Riley, D.O.; Gavett, B.E.; Shenton, M.E.; Lin, A.; Nowinski, C.J.; Cantu, R.C.; McKee, A.C.; Stern, R.A. Chronic traumatic encephalopathy: Neurodegeneration following repetitive concussive and subconcussive brain trauma. Brain Imaging Behav. 2012, 6, 244-254.
10. Rau, T.F.; Kothiwal, A.; Zhang, L.; Ulatowski, S.; Brooks, D.M.; Cardozo-Pelaez, F.; Chopp, M.; Poulsen, D.J. Low dose methamphetamine mediates neuroprotection through a PI3K-AKT pathway. Neuropharmacology 2011, 61, 677-686.
11. Bullock, R.Z.A.; Woodward, J.J.; Myseros, J.; Choi, S.C.; Ward, J.D.; Marmarou, A.; Young, H.F. Factors affecting excitatory amino acid release following severe human head injury. J. Neurosurg. 1998, 89, 507-518.
12. Chan, P.H. Mitochondria and neuronal death/survival signaling pathways in cerebral ischemia. Neurochem. Res. 2004, 29, 1943-1949.
13. Faden, A.I. Neuroprotection and traumatic brain injury: Theoretical option or realistic proposition. Curr. Opin. Neurol. 2002, 15, 707-712.
14. Stokes, G. S; Marwood, J.F. Review of the use of alpha-adrenoceptor antagonists in hypertension. Methods Find Exp. Clin. Pharmacol 1984, 6, 197-204.
15. Strosberg, A.D. Structure, function, and regulation of adrenergic receptors. Protein. Sci. 1993, 2, 1198-1209.
16. Te, A.E. A modern rationale for the use of phenoxybenzamine in urinary tract disorders and other conditions. Clin. Ther. 2002, 24, 851-861; discussion 837.
17. Hamilton, C.A.; Dalrymple, H.W.; Reid, J.L.; Sumner, D.J. The recovery of alpha-adrenoceptor function and binding sites after phenoxybenzamine. An index of receptor turnover? Naunyn. Schmiedebergs Arch. Pharmacol. 1984, 325, 34-41.
18. Rau, T.F.; Kothiwal, A.S.; Rova, A.R.; Brooks, D.M.; Poulsen, D.J. Treatment with low-dose methamphetamine improves behavioral and cognitive function after severe traumatic brain injury. J. Trauma Acute. Care Surg. 2012, 73, S165-S172.
19. Antunes, M.; Biala, G. The novel object recognition memory: Neurobiology, test procedure, and its modifications. Cogn. Process 2012, 13, 93-110.
20. Xiong, Y.; Mahmood, A.; Chopp, M. Animal models of traumatic brain injury. Nat. Rev. Neurosci. 2012, 14, 128-142.
21. Shultz, S.R.; Bao, F.; Omana, V.; Chiu, C.; Brown, A.; Cain, D.P. Repeated mild lateral fluid percussion brain injury in the rat causes cumulative long-term behavioral impairments, neuroinflammation, and cortical loss in an animal model of repeated concussion. J. Neurotrauma 2012, 29, 281-294.
22. Caine, M.; Perlberg, S.; Meretyk, S. A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction. Br. J. Urol. 1978, 50, 551-554.
23. Buchweitz, E.; Weiss, H.R. Effects of phenoxybenzamine or N-methyl chlorpromazine on regional cerebral blood flow: Comparison of central and peripheral alpha adrenergic receptor antagonism. J. Pharmacol. Exp. Ther. 1982, 223, 322-326.
24. Hamill, R.W.; Woolf, P.D.; McDonald, J.V.; Lee, L.A. Kelly, M. Catecholamines predict outcome in traumatic brain injury. Ann. Neurol. 1987, 21, 438-443.
25. Tran, T.Y.; Dunne, I.E. German, J.W. Beta blockers exposure and traumatic brain injury: A literature review. Neurosurg. Focus 2008, 25, E8.
26. Woolf, P.D.; Hamill, R.W.; Lee, L.A.; Cox, C.; McDonald, J.V. The predictive value of catecholamines in assessing outcome in traumatic brain injury. J. Neurosurg. 1987, 66, 875-882.
27. Woolf, P.D.; Hamill, R.W.; Lee, L.A.; McDonald, J.V. Free and total catecholamines in critical illness. Am. J. Physiol. 1988, 254, E287-E291.
28. Kobori, N.; Hu, B.; Dash, P.K. Altered adrenergic receptor signaling following traumatic brain injury contributes to working memory dysfunction. Neuroscience 2011, 172, 293-302.
29. Cimino, M.; Weiss, B. Characteristics of the binding of phenoxybenzamine to calmodulin. Biochem. Pharmacol. 1988, 37, 2739-2745.
30. Yang, K.; Taft, W.C.; Dixon, C.E.; Todaro, C.A.; Yu, R.K.; Hayes, R.L. Alterations of protein kinase C in rat hippocampus following traumatic brain injury. J. Neurotrauma 1993, 10, 287-295.
31. Tomycz, N.D. Friedlander, R.M. α-1 Adrenergic receptor signaling linked to memory dysfunction following brain trauma. Neurosurgery 2011, 68, N16-N18.
32. Vest, R.S.; O'Leary, H.; Coultrap, S.J.; Kindy, M.S.; Bayer, K.U. Effective post-insult neuroprotection by a novel Ca(2+)/ calmodulin-dependent protein kinase II (CaMKII) inhibitor. J. Biol. Chem. 2010, 285, 20675-20682.
33. Zhang, M.; Shan, H.; Gu, Z.; Wang, D.; Wang, T.; Wang, Z.; Tao, L. Increased expression of calcium/calmodulin-dependent protein kinase type II subunit delta after rat traumatic brain injury. J. Mol. Neurosci. 2012, 46, 631-643.
34. Semple, B.D.; Frugier, T.; Morganti-Kossmann, M.C. Role of CCL2 (MCP-1) in traumatic brain injury (TBI): Evidence from severe TBI patients and CCL2-/-mice. J. Cereb. Blood Flow Metab. 2010, 30, 769-782.
35. Semple, B.D.; Frugier, T. Morganti-Kossmann, M.C. CCL2 modulates cytokine production in cultured mouse astrocytes. J. Neuroinflammation 2010, 7, 67.
36. Semple, B.D.; Kossmann, T.; Morganti-Kossmann, M.C. Role of chemokines in CNS health and pathology: A focus on the CCL2/CCR2 and CXCL8/CXCR2 networks. J. Cereb. Blood Flow Metab. 2010, 30, 459-473.
37. Sozzani, S.; Rieppi, M.; Locati, M.; Zhou, D.; Bussolino, F.; Proost, P.; van Damme, J.; Mantovani, A. Synergism between platelet activating factor and C-C chemokines for arachidonate release in human monocytes. Biochem. Biophys. Res. Commun. 1994, 199, 761-766.
38. Sozzani, S.; Zhou, D.; Locati, M.; Rieppi, M.; Proost, P.; Magazin, M.; Vita, N.; van Damme, J.; Mantovani, A. Receptors and transduction pathways for monocyte chemotactic protein-2 and monocyte chemotactic protein-3. Similarities and differences with MCP-1. J. Immunol. 1994, 152, 3615-3622.
39. Ziebell, J.M.; Morganti-Kossmann, M.C. Involvement of pro-and anti-inflammatory cytokines and chemokines in the pathophysiology of traumatic brain injury. Neurotherapeutics 2010, 7, 22-30.
40. Rhodes, J.K.; Sharkey, J.; Andrews, P.J. The temporal expression, cellular localization, and inhibition of the chemokines MIP-2 and MCP-1 after traumatic brain injury in the rat. J. Neurotrauma 2009, 26, 507-525.
41. Prodjosudjadi, W.; Gerritsma, J.S.; Klar-Mohamad, N.; Gerritsen, A.F.; Brujin, J.A.; Daha, M.R.; van Es, L.A. Production and cytokine-mediated regulation of monocyte chemoattractant protein-1 by human proximal tubular epithelial cells. Kidney. Int. 1995, 48, 1477-1486.
42. Prodjosudjadi, W.; Gerritsma, J.S.; van Es, L.A.; Daha, M.R.; Bruijn, J.A. Monocyte chemoattractant protein-1 in normal and diseased human kidneys: An immunohistochemical analysis. Clin. Nephrol. 1995, 44, 148-155.
43. Block, M.L.; Zecca, L.; Hong, J.S. Microglia-mediated neurotoxicity: Uncovering the molecular mechanisms. Nat. Rev. Neurosci. 2007, 8, 57-69.
44. Monje, M.L.; Toda, H.; Palmer, T.D. Inflammatory blockade restores adult hippocampal neurogenesis. Science 2003, 302, 1760-1765.
45. Lloyd, E.; Somera-Molina, K.; van Eldik, L.J.; Watterson, D.M.; Wainwright, M.S. Suppression of acute proinflammatory cytokine and chemokine upregulation by post-injury administration of a novel small molecule improves long-term neurologic outcome in a mouse model of traumatic brain injury. J. Neuroinflammation 2008, 5, 28.
46. Brown, G.C.; Neher, J.J. Inflammatory neurodegeneration and mechanisms of microglial killing of neurons. Mol. Neurobiol. 2010, 41, 242-247.
47. Li, B.; Mahmood, A.; Lu, D.; Wu, H.; Xiong, Y.; Qu, C.; Chopp, M. Simvastatin attenuates microglial cells and astrocyte activation and decreases interleukin-1beta level after traumatic brain injury. Neurosurgery 2009, 65, 179-185; Discussion 185-186.
48. Li, G.Z.; Zhang, Y.; Zhao, J.B.; Wu, G.J.; Su, X.F.; Hang, C.H. Expression of myeloid differentiation primary response protein 88 (Myd88) in the cerebral cortex after experimental traumatic brain injury in rats. Brain Res. 2011, 1396, 96-104.
49. Ling, H.P.; Li, W.; Zhou, M.L.; Tang, Y.; Chen, Z.R.; and Hang, C.H. Expression of intestinal myeloid differentiation primary response protein 88 (Myd88) following experimental traumatic brain injury in a mouse model. J. Surg. Res. 2013, 179, e227-e234.
50. Janssens, S.; Beyaert, R. A universal role for MyD88 in TLR/IL-1R-mediated signaling. Trends Biochem. Sci. 2002, 27, 474-482.
51. Selkirk, J.V.; Stiefel, T.H.; Stone, I.M.; Naeve, G.S.; Foster, A.C.; Poulsen, D.J. Over-expression of the human EAAT2 glutamate transporter within neurons of mouse organotypic hippocampal slice cultures leads to increased vulnerability of CA1 pyramidal cells. Eur. J. Neurosci. 2005, 21, 2291-2205.
52. Noraberg, J.; Kristensen, B.W.; Zimmer, J. Markers for neuronal degeneration in organotypic slice cultures. Brain Res. Brain Res. Protoc. 1999, 3, 278-290.